Prognostic indicators of future disease activity in patients with relapsing multiple sclerosis (MS): an analysis from the AFFIRM study

被引：0
|
作者：
Kappos, L
O'Connor, PW
Havrdova, E
Hutchinson, M
Miller, DH
Phillips, JT
Polman, CH
Lublin, FD
Giovannoni, G
Wajgt, A
Lynn, F
Toal, M
Panzara, MA
Sandrock, AW
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Gen Teaching Hosp, Prague, Czech Republic
[4] St Vincents Univ Hosp, Dublin, Ireland
[5] Inst Neurol, London WC1N 3BG, England
[6] Texas Neurol, Dallas, TX USA
[7] VU Med Ctr, Amsterdam, Netherlands
[8] Mt Sinai Sch Med, New York, NY USA
[9] Silesian Med Univ, Katowice, Poland
[10] Biogen Idec Inc, Cambridge, MA USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2005年 / 238卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [21] A pilot study of monocytes in relapsing remitting multiple sclerosis: Correlation with disease activity
    Taha, Sara, I
    Mohamed, Hala Ghareeb
    Mamdouh, Rasha
    Kamal, Nada E.
    Khater, Shaimaa Sayed
    INNATE IMMUNITY, 2024, 30 (05) : 90 - 95
  • [22] Reducing Rebound Disease Activity in Relapsing Multiple Sclerosis Patients Electively Transitioned from Natalizumab to Teriflunomide
    Cohan, Stanley
    Edwards, Keith
    Gervasi, Tiffany
    Chen, Chiayi
    O'Connor, Judy
    Smoot, Kyle
    Kresa-Reahl, Kiren
    NEUROLOGY, 2017, 88
  • [23] Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil W.
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Hicking, Christine
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (06) : 819 - 827
  • [24] Drivers of therapy switch in relapsing multiple sclerosis: a study from the Italian MS Registry
    Iaffaldano, P.
    Lucisano, G.
    Guerra, T.
    Patti, F.
    Cocco, E.
    De Luca, G.
    Morra, V. Brescia
    Pozzilli, C.
    Zaffaroni, M.
    Sola, P.
    Gasperini, C.
    Salemi, G.
    Bergamaschi, R.
    Lus, G.
    Inglese, M.
    Romano, S.
    Bellantonio, P.
    Coniglio, M. G.
    Maniscalco, G. T.
    Conte, A.
    Lugaresi, A.
    Vianello, M.
    Confalonieri, P. A.
    Capobianco, M.
    Pesci, I.
    Granella, F.
    Totaro, R.
    Marfia, G. A.
    Danni, M. C.
    Cavalla, P.
    Valentino, P.
    Aguglia, U.
    Montepietra, S.
    Ferraro, E.
    Protti, A.
    Spitalieri, D.
    Avolio, C.
    Scarpini, E.
    Maimone, D.
    Tedeschi, G.
    Sessa, M.
    Rovaris, M.
    De Robertis, F.
    Rini, A.
    Bonaventura, A.
    Paolicelli, D.
    Nica, M.
    Amato, M. P.
    Filippi, M.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 388 - 389
  • [25] Natalizumab reduces multiple sclerosis severity: Analysis of patients from the AFFIRM and SENTINEL studies using the multiple sclerosis severity scale
    Herbert, Joseph
    Kappos, Ludwig
    Calabresi, Peter
    Confavreux, Christian
    Galetta, Steven
    Giovannoni, Gavin
    Havrdova, Eva
    Hutchinson, Michael
    Lublin, Fred
    Miller, David
    O'Connor, Paul W.
    Phillips, J.
    Polman, Chris
    Radue, Ernst-Wilhelm
    Rudick, Richard
    Stuart, William
    Wajgt, Andrzej
    Weinstock-Guttman, Bianca
    Wynn, Daniel
    Bacon, Joshua
    Kister, Ilya
    Pace, Amy
    Panzara, Michael
    NEUROLOGY, 2008, 70 (11) : A212 - A212
  • [26] Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients
    Vogt, MHJ
    Floris, S
    Killestein, J
    Knol, DL
    Smits, M
    Barkhof, F
    Polman, CH
    Nagelkerken, L
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 155 (1-2) : 155 - 160
  • [27] Durable effect of alemtuzumab on disease activity in patients with relapsing-remitting multiple sclerosis
    Wiendl, H.
    Arnold, D. L.
    Hupperts, R. M.
    Giovannoni, G.
    Margolin, D. H.
    Kasten, L.
    Havrdova, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 256 - 256
  • [28] High Disease Activity (HDA) definitions in patients with Relapsing Multiple Sclerosis (RMS) receiving placebo in the CLARITY Study
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Dangond, F.
    Hicking, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 202 - 203
  • [29] Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study
    Giovannoni, Gavin
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    NEUROLOGY, 2017, 88
  • [30] Proton magnetic resonance spectroscopy of global metabolic variations as indicators of disease activity in relapsing remitting multiple sclerosis
    Grossman, RI
    Gonen, O
    RADIOLOGY, 2002, 225 : 428 - 428
12345